Key Highlights
- Arecor Therapeutics LSE:AREC is shown up 4.47% on 21 September 2026.
- The company is focused on diabetes and other cardiometabolic diseases using its proprietary Arestat formulation technology.
- Its lead programme, AT278, is an ultra-concentrated 500 U/mL and ultra-rapid-acting insulin being developed with Sequel Med Tech for use with an automated insulin-delivery system.
- Arecor's latest published research on AT278 reported ultra-rapid pharmacokinetic and pharmacodynamic characteristics in people with type 2 diabetes across BMI groups.
- A Phase 2 programme for AT278 is a key upcoming development, with the company working towards clinical progression in the second half of 2026.
- Arecor is also developing an oral peptide delivery platform, initially focused on GLP-1 therapies for diabetes and obesity.
- The company is due to attend the European Association for the Study of Diabetes Annual Meeting in Milan from 28 September to 2 October 2026, providing another near-term industry event to watch.
Why Is Arecor Therapeutics LSE:AREC in Focus on 21 September 2026?
Arecor Therapeutics LSE:AREC is among the notable movers shown on 21 September 2026, with the stock gaining 4.47%.
The move comes as investors continue to monitor the company's clinical-development pipeline, particularly AT278, its proprietary ultra-concentrated and ultra-rapid-acting insulin.
Arecor is developing AT278 in combination with Sequel Med Tech's automated insulin-delivery system. The programme is designed to address the needs of people requiring high daily insulin doses and potentially support smaller, longer-wear insulin-pump systems.
There is no confirmed company announcement identifying one single catalyst for the full 4.47% move on 21 September. Recent trading data show that LSE:AREC had already experienced considerable movement during September, including a 5.56% rise on 16 September.
Why Did Arecor Therapeutics LSE:AREC Rise 4.47% Today?
The 4.47% increase shown for 21 September 2026 comes against a backdrop of continued attention around Arecor's clinical pipeline and upcoming development milestones.
The most important fundamental theme is AT278. The programme is designed around a 500 U/mL insulin formulation with ultra-rapid action, potentially allowing greater insulin capacity in automated delivery systems.
Arecor's latest published research highlighted the pharmacokinetic and pharmacodynamic characteristics of AT278 in type 2 diabetes patients regardless of BMI. The study was published in Diabetes, Obesity and Metabolism during August 2026.
This provides additional clinical information ahead of the company's next development stage.
Why Is AT278 Important for LSE:AREC?
AT278 is currently the central proprietary asset in Arecor's diabetes portfolio.
The formulation combines ultra-high concentration of 500 U/mL with ultra-rapid insulin action. Arecor is developing it with Sequel Med Tech for potential use with the twiist automated insulin-delivery system.
The intended application is particularly relevant for people who require high daily insulin doses. Higher-concentration insulin can potentially allow more insulin to be delivered from a smaller reservoir, while rapid action is intended to improve compatibility with automated delivery.
Arecor says the programme is being prepared for a Phase 2 clinical study involving AT278 and an automated insulin-delivery system.
What Is the Latest AT278 Clinical Development?
The latest 2026 research activity has provided additional visibility on AT278's clinical profile.
A peer-reviewed study published in August examined highly concentrated insulin aspart at 500 U/mL and reported ultra-rapid pharmacokinetic and pharmacodynamic properties in people with type 2 diabetes across different BMI categories.
Earlier clinical work also reported that AT278 demonstrated a significantly accelerated profile compared with Humulin R U-500 in a Phase 1 study, with no safety signals identified in that trial.
The next important question is therefore how the formulation performs in a larger and more targeted clinical-development programme.
Could Phase 2 Development Become a Major Catalyst for LSE:AREC?
Phase 2 development is one of the key areas investors are watching.
Arecor previously received positive regulatory feedback on the proposed Phase 2 study design for AT278 in combination with an automated insulin-delivery system. The planned study uses continuous glucose-monitoring-derived measures and time-in-range as important efficacy measures.
The company has been working with Sequel on the preparation required for the programme.
Progress towards Phase 2 could therefore provide an important series of milestones for LSE:AREC, including clinical-trial preparation, regulatory activity, funding and Partnership developments.
Why Is the Oral Peptide Platform Important for Arecor?
Arecor's strategy extends beyond insulin.
The company is also developing a technology platform for the oral delivery of peptides, with an initial focus on GLP-1 receptor agonists.
The objective is to address one of the major challenges associated with peptide medicines: delivering biologically active molecules orally while maintaining sufficient bioavailability.
A successful oral-delivery technology could potentially broaden the company's exposure to diabetes, obesity and other cardiometabolic markets. Arecor identifies oral peptide delivery as a second major proprietary development portfolio alongside its diabetes programme.
Why Is the September Diabetes Conference Relevant to LSE:AREC?
Arecor is scheduled to attend the European Association for the Study of Diabetes Annual Meeting in Milan from 28 September to 2 October 2026.
The event arrives shortly after the company's August publications on AT278 and could provide an opportunity for further scientific and industry discussion around the programme.
For LSE:AREC, conference activity can be relevant because clinical-stage biotechnology companies often use major medical meetings to present research, discuss development programmes and engage with potential partners.
What Should Investors Watch Next for LSE:AREC?
The principal areas to monitor include AT278's progression towards Phase 2, regulatory and clinical-development milestones, the relationship with Sequel Med Tech and any broader commercialisation discussions.
Investors may also watch the oral peptide programme for new preclinical data and development milestones.
Arecor's partnership strategy is another important Factor because its Business model includes working with pharmaceutical, biotechnology and medical-technology companies around its proprietary formulation platform.
The September diabetes conference and subsequent clinical-development updates could therefore provide additional information about the company's pipeline.
Could Arecor Therapeutics LSE:AREC Remain in Focus After the 4.47% Rise?
The 4.47% rise on 21 September 2026 comes as Arecor approaches a potentially important period for its clinical pipeline.
AT278 remains the central focus, supported by recent peer-reviewed research, its development partnership with Sequel Med Tech and preparations for Phase 2 clinical development. The oral peptide platform provides an additional technology opportunity in the diabetes and obesity markets.
For LSE:AREC, future market attention is likely to centre on clinical progress, regulatory milestones, partnership developments and further evidence supporting the commercial potential of its proprietary technologies.






Please wait processing your request...